Cincinnati Children's Hospital Medical Center

Global firm BTS Group joins Cincinnati Innovation District as corporate partner

Retrieved on: 
Tuesday, February 21, 2023
Technology, Other Professional Services, Health, Human Resources, Consulting, Training, Other Education, Professional Services, University, Software, Education, General Health, Hospitals, Health Technology, ESG, CID, Procter & Gamble, Partnership, UC, Kroger, Research, Culture, Environment, Faculty, BTS, Fifth Third Bank, Innovation Hub, Student, Cincinnati Children's Hospital Medical Center, STEM, Management, Cincinnati metropolitan area

BTS , a world-leading strategy implementation firm based out of Stockholm, Sweden, has joined the Cincinnati Innovation District as a corporate partner.

Key Points: 
  • BTS , a world-leading strategy implementation firm based out of Stockholm, Sweden, has joined the Cincinnati Innovation District as a corporate partner.
  • The company will locate its global innovation, digital transformation and ESG center within the University of Cincinnati 1819 Innovation Hub, the nerve center of the CID.
  • “We look forward to showcasing the Cincinnati story globally and bringing our ‘big hearted and high performing’ culture to the community.”
    BTS joins several Fortune 100 and 500 companies, including Kroger, Fifth Third Bank and Procter & Gamble, as corporate partners in the Cincinnati Innovation District.
  • “The Cincinnati Innovation District offers a wealth of new opportunities for BTS,” says Peter Mulford, chief innovation officer at BTS.

Silver Sponsor Molecular Devices at Society for Laboratory Automation and Screening 2023 International Conference and Exhibition

Retrieved on: 
Wednesday, February 22, 2023
Society, Organoid, Molecular Devices, Brain, Immortalised cell line, HUB, Magnetic 3D bioprinting, Biology, Workflow, Custom, Drug development, Automation, Acquisition, Software, Society for Laboratory Automation and Screening, Biomedical Research, CCHMC, Cincinnati Children's Hospital Medical Center, Poster, Cell, Laboratory automation, BAB, Good Samaritan Hospital Medical Center (West Islip, New York), SLAS, SAN, Exhibition, International Conference on Bioinformatics, Drug discovery, Conference, Pancreatic cancer, 3D, Mobile phone, Fine chemical, Medical imaging, Medical device, Research

SAN JOSE, Calif., Feb. 22, 2023 /PRNewswire-PRWeb/ -- Molecular Devices, LLC., a leading provider of high-performance life science solutions, is demonstrating its latest automated, high-throughput technology at this year's Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition from February 25 – March 1, 2023, in San Diego, Calif.

Key Points: 
  • Through a strategic acquisition and industry collaborations, Molecular Devices is demystifying the process of creating high-volume, viable, and reproducible organoids for drug discovery.
  • When complemented by Molecular Devices' high-performance, automated hardware and software solutions, the offering is a first-of-its-kind, turnkey solution for organoid development, screening, and analysis.
  • Novel analysis of neural outgrowth in 3D reconstructed human brain micro-tissues with application in compound screening on Tuesday, February 28, 2023: Poster by Molecular Devices.
  • For an overview of where to find Molecular Devices at SLAS 2023, visit the company's webpage here .

TeamConnor Childhood Cancer Foundation Announces Grant Recipients in Pediatric Cancer Research for 2023

Retrieved on: 
Thursday, February 9, 2023
DREAM, Juvenile myelomonocytic leukemia, Medicine, Glioma, Speedway Children's Charities, Hospital, St. Baldrick's Foundation, Transplant, Cancer, Lymphoma, Einstein Medical Center Philadelphia, Boston Children's Hospital, Bone marrow, Connor, Texas Motor Speedway, Research, Cincinnati Children's Hospital Medical Center, Neoplasm, Child, Moon, Stand Up to Cancer, Immune system, Dana–Farber Cancer Institute, Gene, Disease, Neuroblastoma, In Honor: A Compilation to Beat Cancer, Partnership, Genomics, Dana, Malignant peripheral nerve sheath tumor, Vaccine, Pharmaceutical industry, Dentistry

DALLAS, Feb. 9, 2023 /PRNewswire/ -- The TeamConnor Childhood Cancer Foundation is proud to continue its work towards eradicating pediatric cancer by awarding $500,000 to multiple research grantees at five national institutions to fund their childhood cancer research work in 2023. As non-profit fundraising opportunities continue to be a challenge, the organization is thankful for the loyal donors, generous foundation grants, and community partners who share in the fight to cure pediatric cancers.

Key Points: 
  • DALLAS, Feb. 9, 2023 /PRNewswire/ -- The TeamConnor Childhood Cancer Foundation is proud to continue its work towards eradicating pediatric cancer by awarding $500,000 to multiple research grantees at five national institutions to fund their childhood cancer research work in 2023.
  • The DREAM team was established as the pediatric cancer research group for Stand Up To Cancer.
  • For more information on how to join the fight against childhood cancer, please visit teamconnor.org or follow TeamConnor Childhood Cancer Foundation on Instagram, Twitter, LinkedIn, YouTube and Facebook.
  • For more information on how to join the fight against childhood cancer, please visit teamconnor.org or follow TeamConnor Childhood Cancer Foundation on Facebook, Instagram, Twitter, LinkedIn, YouTube.

Top Discoveries from a Record-Breaking Year for Cincinnati Children's

Retrieved on: 
Wednesday, February 8, 2023
Cardiovascular disease, University, Stomach, Organoid, Vaccine, Mother, Pediatrics, Life, Infection, Immunity, The New England Journal of Medicine, Health, Cincinnati Children's Hospital Medical Center, Child, Risk, Cell Stem Cell, Student, Antibody, Pregnancy, MPH, Faculty, Date, Muscular dystrophy, COVID-19, Cancer, Mental health, Pharmaceutical industry, Nursing, Nature, MD

CINCINNATI, Feb. 8, 2023 /PRNewswire/ -- Even as research teams raced to study new vaccines and understand the potential impact of long-term COVID-19 symptoms, experts at Cincinnati Children's Hospital Medical Center made important discoveries during fiscal 2022 on a wide range of child health conditions including mental health, cancer, and many other diseases. 

Key Points: 
  • The latest Research Annual Report from Cincinnati Children's, one of the world's top pediatric academic medical centers.
  • The study , published in Cell Stem Cell, reflects the latest in a string of organoid medicine breakthroughs achieved at Cincinnati Children's.
  • They found five risk factors that count, and report that taking early steps to address those risks can pay off later in life.
  • Findings were published in The New England Journal of Medicine.

Team Toyota Athlete Alana Nichols Shares Passion for Child Passenger Safety in Collaboration with Buckle Up for Life

Retrieved on: 
Tuesday, January 24, 2023
Safety, Sienna, Caregiver, Female, Buckle, Cincinnati Children's Hospital Medical Center, Child, Education, Video, Human, Partnership, Toyota, PSA, Gold, Nichols, Life, Parent, U.S.–Afghanistan Strategic Partnership Agreement, Toyota Motor North America, Paralympic Games, Alanna, Residential care, Toy, Mobility

PLANO, Texas, Jan. 24, 2023 /PRNewswire/ -- Three-time Paralympic Gold Medalist Alana Nichols is teaming up with Buckle Up for Life – a national child passenger safety program created by Toyota and Cincinnati Children's Hospital Medical Center – to promote the importance of child passenger safety in vehicles.

Key Points: 
  • "As a Paralympic athlete, it's a tremendous privilege to have a public platform from which I can speak," said Nichols.
  • "And, now as a mother, one of my strongest passions is to help parents and caregivers fully appreciate the importance of child passenger safety."
  • Nichols shares her personal story in the PSA, which was shot at Nichols' home.
  • "Alana's passion for child passenger safety and her partnership with Buckle Up for Life will help raise awareness to help save lives," said Gloria Del Castillo, child passenger safety expert at Cincinnati Children's and senior specialist of community engagement for Buckle Up for Life.

Cincinnati Children's Opens First-of-its-Kind Heart and Mind Wellbeing Center in United States

Retrieved on: 
Tuesday, January 24, 2023
AHA, Science, American Heart Association, Cincinnati Children's Hospital Medical Center, Diagnosis, Hope, Circulant matrix, Ventricular septal defect, Birth defect, CHD, Partnership, The American Heart Institute, Social, Research, Congenital heart defect, Heart, Acute stress disorder, Parent, Patient, Anxiety, Depression, Multimedia, Doctor of Philosophy, Mental health, Pharmaceutical industry, Nursing

CINCINNATI, Jan. 24, 2023 /PRNewswire/ -- Cincinnati Children's Hospital Medical Center is excited to announce the opening of its Heart and Mind Wellbeing Center , the first of its kind in the United States.

Key Points: 
  • CINCINNATI, Jan. 24, 2023 /PRNewswire/ -- Cincinnati Children's Hospital Medical Center is excited to announce the opening of its Heart and Mind Wellbeing Center , the first of its kind in the United States.
  • The Heart and Mind Wellbeing Center was created to provide comprehensive psychological support and mental health care tailored for families affected by Congenital Heart Disease (CHD) .
  • "Congenital heart disease can profoundly affect families emotionally," said Nadine Kasparian, PhD , psychologist and director of Cincinnati Children's Heart and Mind Wellbeing Center.
  • Research is also an integral part of the Heart and Mind Wellbeing Center, which is conducting groundbreaking research into parent mental health in conjunction with the Heart Institute's Fetal Heart Program at Cincinnati Children's.

New Guidelines Cite Oral Levothyroxine Solution as an Option for Treating Congenital Hypothyroidism (CH)

Retrieved on: 
Thursday, January 12, 2023
Cincinnati Children's Hospital Medical Center, Congenital hypothyroidism, Hypothyroidism, University, University of Cincinnati, Pediatrics (journal), Caregiver, American Academy of Pediatrics, Medicine, ATA, Safety, PES, FDA, American Thyroid Association, Craniosynostosis, Water, Mouth, CH, Patient, Thyroid hormones, Lactose, American Academy, Journal, Hormone Research in Paediatrics, IBSA, Glycerol, AAP, Birth defect, Pharmaceutical industry, Pediatrics

PARSIPPANY, N.J., Jan. 12, 2023 /PRNewswire/ -- The American Academy of Pediatrics (AAP), the Pediatric Endocrine Society (PES) and the American Thyroid Association (ATA) have published new guidelines for the treatment of congenital hypothyroidism (CH). For the first time, these leading medical societies cite levothyroxine oral solution as an option for managing patients with CH. Congenital hypothyroidism is a condition affecting up to 1 in every 2,000-4,000 live births in the United States annually. It is a leading cause of intellectual deficiency among infants.1 CH is typically treated with levothyroxine, a synthetic thyroid hormone that is administered daily to restore thyroid hormones to normal levels. Tirosint-SOL (levothyroxine sodium) oral solution is the leading FDA-approved levothyroxine oral solution currently available in the US.

Key Points: 
  • For the first time, these leading medical societies cite levothyroxine oral solution as an option for managing patients with CH.
  • Tirosint-SOL (levothyroxine sodium) oral solution is the leading FDA-approved levothyroxine oral solution currently available in the US.
  • A randomized clinical study published in the journal Hormone Research in Pediatrics examined the efficacy and safety of treating infants newly diagnosed with CH with levothyroxine oral solution in lieu of traditional levothyroxine tablet formulations.
  • In total, 78 infants with congenital hypothyroidism (CH) were studied.2 The study's authors concluded that levothyroxine oral solution was able to successfully treat CH patients to their therapeutic goals.

Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics

Retrieved on: 
Wednesday, January 11, 2023
Paragon, Clinical trial, Injury, Pain, Disease, Cincinnati Children's Hospital Medical Center, Insomnia, MD, Distress, Yale Global Tic Severity Scale, Tourette syndrome, Ecopipam, Tic, Social stigma, Patient, Mortality, Pediatrics, Weight gain, Antipsychotic, Somnolence, Fatigue, Headache, Editor's Note, Hospital, Movement disorders, Pharmaceutical industry, Birth control

CHICAGO, Jan. 11, 2023 /PRNewswire/ -- A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the total number of tics compared to placebo, according to a study published today in the journal Pediatrics.

Key Points: 
  • The study, known as the D1AMOND trial, was an international, multicentered randomized, placebo-controlled trial of ecopipam in Tourette syndrome.
  • The primary outcome was the mean change in Yale Global Tourette Severity Total Tic Score.
  • The key secondary outcome of Clinical Global Impression of Tourette Syndrome Severity also showed improvement in the ecopipam group (p= 0.03).
  • Ecopipam is the lead candidate for Emalex Biosciences, a clinical-stage biopharmaceutical company founded by Paragon Biosciences.

Cincinnati Children's promotes Oliver Rhine to senior VP & chief strategy officer

Retrieved on: 
Wednesday, January 4, 2023
Well, Strategic planning, Purdue University, Child, Cincinnati Children's Hospital Medical Center, Education, Critical care, Health, News, University, Senior, Business, Safety, Hospital, U.S. News & World Report, University of Chicago Booth School of Business, Multimedia, Rhine, Culture, MBA, Research, Hotel manager, Management, Medicine, MD

CINCINNATI, Jan. 4, 2023 /PRNewswire/ -- Oliver Rhine has been promoted to Senior Vice President & Chief Strategy Officer of Cincinnati Children's Hospital Medical Center. 

Key Points: 
  • CINCINNATI, Jan. 4, 2023 /PRNewswire/ -- Oliver Rhine has been promoted to Senior Vice President & Chief Strategy Officer of Cincinnati Children's Hospital Medical Center.
  • Oliver Rhine joins the 11-person Executive Team led by president and CEO Steve Davis, MD.
  • A member of the team at Cincinnati Children's for the last decade, Rhine most recently was vice president for strategic planning.
  • "Oliver's expertise in strategy and planning has already contributed to the ongoing work of Cincinnati Children's," Davis said.

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both

Retrieved on: 
Monday, December 12, 2022
University, OH, Cincinnati Children's Hospital Medical Center, UT Health East Texas - North Campus, AOM, Norovirus, Security (finance), Government, Hospital, FDA, BWV, University of Texas Health Science Center at San Antonio, Risk, Vaccine, Streptococcus pneumoniae, VLP, Media, Infection, Nov, Malaria, Projection, Water, S&P, Pneumonia, Research, COVID-19, Form, Pharmaceutical industry, Maxim
Key Points: